Michael Carlson, MD
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1386639219
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $328,860 of the $381,306 with a category attached, or 86.2%. 60 manufacturers reported payments, led by Novo Nordisk at 50.3% of the total. Reporting peaked in 2019 at $87,443 and has fallen 68.7% since, to $27,345 in 2025. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,788 payments — averaging $213.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$192K
- Amgen$58K
- Lilly USA, LLC$36K
- Boehringer Ingelheim$30K
- AstraZeneca$28K
- AbbVie$19K
- plus $16K from 54 others
What the payments were for
- Consulting fees$2,9251%
- Speaking & faculty fees$328,86086%
- Travel & lodging$15,5334%
- Food & beverage$33,9299%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$100,688
- Ozempic$62,243
- JARDIANCE$61,163
- EVENITY$29,033
- FARXIGA$26,630
- Prolia$26,321
- Synthroid$16,921
- Tresiba$10,687
- Xultophy 100/3.6$2,635
- Korlym$2,383
- iLet Bionic Pancreas$1,271
- CeQur Simplicity$409
- iLet Insulin Infusion Kit Inset$278
- iLet Insulin Infusion Kit Contact Detach$278
- EVERSENSE E3 SMART TRANSMITTER KIT$151
- MINIMED 780G$149
- TZIELD$148
- Yorvipath$123
How this compares
$381,306 in reported general payments places this provider in the 90th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $249,767 |
| JardianceEmpagliflozin | 94 | $121,623 |
| TrulicityDulaglutide | 102 | $119,235 |
| MounjaroTirzepatide | 57 | $72,692 |
| FarxigaDapagliflozin Propanediol | 48 | $55,986 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $52,567 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $34,310 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $28,574 |
| Cinacalcet Hcl | 77 | $16,110 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $14,494 |
| SynthroidLevothyroxine Sodium | 119 | $12,247 |
| Novolog FlexpenInsulin Aspart | 35 | $12,053 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $11,274 |
| TradjentaLinagliptin | 11 | $11,078 |
| Testosterone | 32 | $8,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $191,927 | $252,429170 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $36,314 | $197,048174 claims |
| Boehringer IngelheimJardiance, Tradjenta | $30,418 | $132,701105 claims |
| AstraZenecaFarxiga | $28,446 | $55,98648 claims |
| MerckJanumet Xr | $287 | $14,49412 claims |
| AbbVieSynthroid | $19,447 | $12,247119 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,119 | $11,27412 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $63 | $2,185237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Nashville
- Craig WierumNashville$1.3M
- Terri JerkinsNashville$567K
- Kathryn DahirNashville$225K
- Rodney SnowNashville$181K
- Annis MarneyNashville$26K
- Emily NeelyNashville$21K
- Amanda DanielNashville$20K
- Juliana MatthewsNashville$15K
- Christopher BowmanNashville$14K
- Cheryl FasslerNashville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.